These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17574989)

  • 1. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.
    Rossin R; Berndorff D; Friebe M; Dinkelborg LM; Welch MJ
    J Nucl Med; 2007 Jul; 48(7):1172-9. PubMed ID: 17574989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
    Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
    J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
    Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
    Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
    Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
    Demartis S; Tarli L; Borsi L; Zardi L; Neri D
    Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-affinity human antibody that targets tumoral blood vessels.
    Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
    Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-α-Methyl-Phenylalanine for Tumor PET Imaging.
    Hanaoka H; Ohshima Y; Suzuki Y; Yamaguchi A; Watanabe S; Uehara T; Nagamori S; Kanai Y; Ishioka NS; Tsushima Y; Endo K; Arano Y
    J Nucl Med; 2015 May; 56(5):791-7. PubMed ID: 25814518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
    Viti F; Tarli L; Giovannoni L; Zardi L; Neri D
    Cancer Res; 1999 Jan; 59(2):347-52. PubMed ID: 9927045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis.
    Wyss MT; Spaeth N; Biollaz G; Pahnke J; Alessi P; Trachsel E; Treyer V; Weber B; Neri D; Buck A
    J Nucl Med; 2007 Apr; 48(4):608-14. PubMed ID: 17401099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.
    Santimaria M; Moscatelli G; Viale GL; Giovannoni L; Neri G; Viti F; Leprini A; Borsi L; Castellani P; Zardi L; Neri D; Riva P
    Clin Cancer Res; 2003 Feb; 9(2):571-9. PubMed ID: 12576420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.
    Czabanka M; Parmaksiz G; Bayerl SH; Nieminen M; Trachsel E; Menssen HD; Erber R; Neri D; Vajkoczy P
    Eur J Cancer; 2011 May; 47(8):1276-84. PubMed ID: 21396810
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.